Oxford Biomedica plc (OXB) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oxford Biomedica Plc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.257 Hello, and welcome to the OXB's 2025 Interim Results 00:00:05.257 -- 00:00:07.179 Presentation. 00:00:07.179 -- 00:00:12.345 We are joined today by Dr. Frank Mathias, Chief Executive Officer, Dr. 00:00:12.345 -- 00:00:16.810 Lucinda Crabtree, Chief Financial Officer, and Dr. 00:00:16.810 -- 00:00:20.674 Sébastien Ribault, Chief Business Officer. 00:00:20.674 -- 00:00:25.920 There will be a Q&A session following the presentation, and if you'd like to ask a question, 00:00:25.920 -- 00:00:30.203 please signal by pressing star 1 on your keypad. 00:00:30.203 -- 00:00:35.369 We ask that please limit your questions to just one 00:00:35.369 -- 00:00:38.273 with a follow-up, if necessary. 00:00:38.273 -- 00:00:40.716 I would now like to hand the call over to Dr. 00:00:40.716 -- 00:00:44.558 Franck Mathias. Please go ahead. 00:00:44.761 -- 00:00:48.866 Good afternoon, everyone, or good morning, depending where you are. 00:00:48.866 -- 00:00:53.211 So, for those on the other side of the ocean, good morning, and thank you for joining 00:00:53.211 -- 00:00:58.908 us for OXB's 2025 Interim Results Presentation. 00:00:58.908 -- 00:01:03.673 It's a pleasure to be with you today, virtually this time. 00:01:03.673 -- 00:01:09.058 With me today, as already said, is our Chief Financial Officer, Lucy Cretry, 00:01:09.058 -- 00:01:14.083 who came on board just over a year ago and quickly established herself 00:01:14.083 -- 00:01:19.428 as an integral part of the team. And with our Chief Business 00:01:19.428 -- 00:01:24.573 Officer, Sébastien Ribaud, who plays a key role in driving our commercial 00:01:24.573 -- 00:01:29.671 progress. Next slide, please. So here, obviously, is our 00:01:29.671 -- 00:01:34.737 legal disclaimer, as always, as a quick rem...